KHB(SZ:002022)2023-11-30 10:57Company Overview - Shanghai Kehua Bio-engineering Co., Ltd. was established in 1981 and is the first IVD listed company on the Shenzhen Stock Exchange [2] - The company specializes in the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, covering molecular diagnostics, biochemical diagnostics, immunodiagnostics, and rapid diagnostics [2] - Kehua Bio has a comprehensive product line and operates R&D and production bases in Shanghai, Xi'an, the Guangdong-Hong Kong-Macao Greater Bay Area, Suzhou, and Italy [2] Market Presence - The company's products are distributed across 30 provinces and municipalities in China, serving over 12,000 hospitals and more than 500 disease control centers, blood centers, blood stations, biopharmaceutical companies, and research institutes [2] - Kehua Bio exports to over 100 countries and regions [2] Strategic Focus - The company aims to enhance its international market competitiveness by focusing on China and emerging markets while maintaining a presence in developed countries [3] - It leverages its Italian subsidiary TGS's sales network in Europe to actively explore new markets [3] Share Repurchase Plan - On October 30, 2023, the company announced a share repurchase plan with a total fund of no less than RMB 100 million and no more than RMB 200 million, with a maximum repurchase price of RMB 11 per share [4] - The repurchase period is set for 12 months from the board's approval date, and as of October 31, 2023, the company has not yet implemented the repurchase [4] Financial Strategy - The company has sufficient cash flow and is cautiously considering investment and acquisition plans in the IVD industry [4] - It plans to respond to market competition by focusing on three strategic areas: enhancing internal capabilities, fostering international collaborations, and expanding overseas operations [4] Response to Market Challenges - The company has experienced a decline in revenue due to market changes, intensified competition, and the implementation of centralized procurement policies [4] - It views centralized procurement as both a challenge and an opportunity, aiming to strengthen its core products and optimize the supply chain to reduce costs and increase efficiency [4]